Pervasis secures additional funding
Pervasis Therapeutics Inc. today announced that it has secured $9.75 million in additional financing.
The Cambridge company focuses on regenerative cell-based therapies and devices,
Investors in the financing round include Flagship Ventures of Cambridge; Polaris Venture Partners, which has offices in Waltham; and Highland Capital Partners, which has offices in Lexington.
Pervasis said the new investment will support further development of its Vascugel blood vessel repair therapeutic, presently in two Phase II clinical trials.
The investment will also support continuing research into expanding the product’s projected uses into additional vascular and non-vascular applications, Pervasis said.
(By Chris Reidy, Globe staff)
